SAMOS schreef op 21 juni 2022 17:28:
Upcoming Milestones
CYAD-211 in r/r MM
Enrollment in the cohorts evaluating enhanced
lymphodepletion is ongoing in the CYAD-211
IMMUNICY-1 trial and additional data from the
trial are expected in the second half of 2022
shARC Franchise
Exploration continues for allogeneic NKG2D
receptor CAR T candidates currently in the
discovery stage that leverage the shARC
platform